1019021-64-7

Basic information

• Product Name: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-Methyl-
• Synonyms: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-Methyl-
• CAS NO: 1019021-64-7
• Molecular Formula: C9H8N2O2
• Molecular Weight: 176.17202
• Mol File: 1019021-64-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-Methyl-(1019021-64-7)
• EPA Substance Registry System: IMidazo[1,2-a]pyridine-3-carboxylic acid, 6-Methyl-(1019021-64-7)

Safety Data

• Hazardous Substances Data: 1019021-64-7(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyridine-3-carboxylic acid, 6-methyl- is a chemical compound with the molecular formula C9H7N3O2. It is a derivative of imidazo[1,2-a]pyridine, which is a fused heterocyclic compound containing both an imidazole and a pyridine ring. The presence of a carboxylic acid group and a methyl group at the 6-position of the imidazo[1,2-a]pyridine-3-carboxylic acid molecule gives the compound its specific properties and reactivity. This chemical compound is likely to be used in pharmaceutical applications, due to its potential pharmacological properties and biological activities. More research may be needed to fully understand the potential uses and effects of imidazo[1,2-a]pyridine-3-carboxylic acid, 6-methyl- in various applications.

Downstream Products

• 1426133-25-6 methyl 3-(3-(4-methyl-3-(6-methylimidazo[1,2-a]pyridine-3-carboxamido)phenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRcalpha PDGFRbeta) kinases